31/03/2020 1:05 am Welcome to isteroids.com - BLOG

Friday 04, Feb 2011

  Rituximab reduces chronic GVHD after allogeneic stem cell transplants

Posted By
Pin it Share on Tumblr

Rituximab reduces chronic GVHD after allogeneic stem cell transplantsRituximab prophylaxis could be of great use for reducing the incidence of chronic, steroid-requiring graft-vs.-host disease in patients who undergo allogeneic stem cell transplants, according to suggestions by investigators at the annual meeting of the American Society of Hematology.

Dr. Joseph Antin, chief of the stem cell transplantation program at the Dana-Farber Cancer Institute in Boston, reported the 1-year cumulative incidence of chronic graft-vs.-host disease (GVHD) among 64 allogeneic stem cell recipients who received prophylactic rituximab (Rituxan) was about 40%, compared with about 65% for historical controls.

The study is supported by Genentech, Gateway for Cancer Research, and the Stem Cell Cyclists of the Pan-Mass Challenge.

Wednesday 21, Jul 2010

  B-cell depletion therapy effective for treating refractory patients

Posted By
Pin it Share on Tumblr

B-cell depletion therapy effective for treating refractory patientsAccording to a study presented at EULAR 2007, the Annual European Congress of Rheumatology in Barcelona, Spain, 36 percent of patients afflicted with refractory systemic lupus erythematosus (SLE or lupus) could notice improvements after undergoing B-cell depletion therapy (BCDT) and do not feel or need standard immunosuppressive agents in the future.

It is worth noting here that reducing the number of B-cells in the system by B-cell depletion therapy is considered as a potential therapy for SLE patients who are unresponsive to other forms of treatment.

It was revealed by co-author of the paper, Professor David Isenberg, from University College London in the United Kingdom that the study results are encouraging and demonstrate that BCDT could be rated as a promising therapeutic option for lupus patients and is effective to reduce the need for continuous immunosuppressive therapy.

Saturday 10, Jul 2010

  Rituximab found effective for treating kidney disorder

Posted By
Pin it Share on Tumblr

Rituximab found effective for treating kidney disorderMembranous nephropathy, a kidney disorder, can be effectively treated with Rituximab. This finding appeared in the April 2009 print issue of the Clinical Journal of the American Society of Nephrology (CJASN).

Steroids, chemotherapeutic agents, and calcineurin inhibitors are some of the presently available options for treating the disorder but all of these options have some side effects.

Andrew Bomback, MD (University of North Carolina Kidney Center), and his colleagues made comparisons about the effects of rituximab therapy to treat patients afflicted against nephropathy after conducting the first systematic review of rituximab use in patients with membranous nephropathy.

Wednesday 30, Jun 2010

  Lupus patients to benefit from Rituximab

Posted By
Pin it Share on Tumblr

Lupus patients to benefit from RituximabA drug presently used for treating cancer patients could be used to treat patients with lupus and suffering from complications of the central nervous system, as per rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria.

The drug, Rituximab, is effective to provide relief to patients afflicted with lupus and could be considered as a gentle form of treatment that can last up to a period of six months with little to no side effects, according to Clinical professor Michael Neuwelt, at the University of California San Francisco and Stanford University.

Lupus is a health complication characterized by reduced quality of life and symptoms such as pain, inflammation, and diffused damage to many body organs.

Monday 21, Jun 2010

  Membranous nephropathy possible of being treated with Rituximab

Posted By
Pin it Share on Tumblr

Membranous nephropathy possible of being treated with RituximabA disorder of the kidneys, membranous nephropathy, can be treated with Rituximab. The drug can help patients afflicted with the kidney disorder by offering them dramatic relief, as per findings appearing in the April 2009 print issue of the Clinical Journal of the American Society of Nephrology (CJASN).

Andrew Bomback, M.D., University of North Carolina Kidney Center and his colleagues, made comparisons between rituximab therapy with nephropathy and found Rituximab to be a better choice. In the past, treatment options for the disorder were limited to steroids, calcineurin inhibitors, and chemotherapeutic agents, all of which have some side effects.

It was remarked by Dr. Bomback that the use of Rituximab must be limited to research setting till efficacy of the same is confirmed by future studies.

Wednesday 14, Apr 2010

  Patients suffering from lupus get relief with Rituximab

Posted By
Pin it Share on Tumblr

Patients suffering from lupus get relief with RituximabRituximab, which is currently indicated to patients suffering from cancer, can also prove effective for providing relief to patients with lupus and suffering from complications of the central nervous system, as per rheumatologists at the Annual European Congress of Rheumatology in Vienna, Austria.

Lupus is an immune system disorder that characterizes an attack by the human body on itself leading to diffused damage to several body organs besides resulting in inflammation and pain.

Clinical professor Michael Neuwelt, at the University of California San Francisco and Stanford University, said that Rituximab proves effective and may be classified as a gentler treatment form, which can last up to six months with a low risk of any side effect.

Tuesday 13, Apr 2010

  Membranous nephropathy may be treated with Rituximab

Posted By
Pin it Share on Tumblr

Membranous nephropathy may be treated with RituximabMembranous nephropathy, a disorder of kidney, can be effectively treated with Rituximab. This finding was disclosed in the April 2009 print issue of the Clinical Journal of the American Society of Nephrology (CJASN).

The effect of rituximab therapy for treating patients struggling against nephropathy was compared by Andrew Bomback, MD (University of North Carolina Kidney Center), and his colleagues after conducting the first systematic review of rituximab use in patients with membranous nephropathy.

Presently, treatment options are limited to calcineurin inhibitors, steroids, and chemotherapeutic agents, all of which have some side effects.

It was remarked by Dr. Bomback that studies in future are required for confirming value of this drug and the use should only be done in research settings till that time.

Thursday 11, Mar 2010

  New method for attacking inflammation in Graves’ Eye Disease

Posted By
Pin it Share on Tumblr

New method for attacking inflammation in Graves' Eye DiseaseRituximab can prove effective when it comes to treating patients with severe Graves‘ eye disease. The drug is useful when it comes to offering benefits such as rapid improvement of symptoms and improved vision.

This finding was disclosed by Raymond S. Douglas, M.D., Ph.D., an oculoplastics specialist who recently joined the faculty of the U-M Kellogg Eye Center, highlighted the efficacy of this drug in the online October issue of Ophthalmology.

Douglas remarked that Rituximab can calm inflammation, stop progression of the disease, and save patients from needing surgery. The drug works by depleting B cells, which are the body’s normal antibody-producing cells that go awry in autoimmune diseases.

Thursday 25, Feb 2010

  New way for attacking inflammation in Graves’ Eye Disease

Posted By
Pin it Share on Tumblr

New way for attacking inflammation in Graves' Eye DiseaseRituximab has the potential of offering considerable relief to patients with Graves’ eye disease and this relief may be in the form of rapid improvement of their symptoms and improved vision besides significant reduction in the level of inflammation around the eyes.

The drug is also effective for patients who have remained unresponsive to steroids, a common treatment for Graves’ eye disease.

Raymond S. Douglas, M.D., Ph.D., an oculoplastics specialist who recently joined the faculty of the U-M Kellogg Eye Center, reported on the potential of the drug in the online October issue of Ophthalmology.

Tuesday 09, Feb 2010

  Membranous nephropathy treatable with Rituximab

Posted By
Pin it Share on Tumblr

Membranous nephropathy treatable with RituximabRituximab can prove to be an effective form of treatment when it comes to providing relief to patients suffering from membranous nephropathy, a kidney disorder.

This finding appeared in an issue of the Clinical Journal of the American Society of Nephrology (CJASN).

The beneficial effect of Rituximab was compared against nephropathy in terms of benefits during a systematic review conducted by Andrew Bomback, MD (University of North Carolina Kidney Center), and his colleagues.

It was remarked by Dr. Bomback that future studies would be crucial in ascertaining the true value of this drug and use of the drug must be made in research settings only till new studies are drawn.

Next »